102 related articles for article (PubMed ID: 29311070)
1. Novel Pyrimidines as Antitubercular Agents.
Inoyama D; Paget SD; Russo R; Kandasamy S; Kumar P; Singleton E; Occi J; Tuckman M; Zimmerman MD; Ho HP; Perryman AL; Dartois V; Connell N; Freundlich JS
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311070
[No Abstract] [Full Text] [Related]
2. Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).
Cherian J; Choi I; Nayyar A; Manjunatha UH; Mukherjee T; Lee YS; Boshoff HI; Singh R; Ha YH; Goodwin M; Lakshminarayana SB; Niyomrattanakit P; Jiricek J; Ravindran S; Dick T; Keller TH; Dartois V; Barry CE
J Med Chem; 2011 Aug; 54(16):5639-59. PubMed ID: 21755942
[TBL] [Abstract][Full Text] [Related]
3. The synthesis and evaluation of triazolopyrimidines as anti-tubercular agents.
Zuniga ES; Korkegian A; Mullen S; Hembre EJ; Ornstein PL; Cortez G; Biswas K; Kumar N; Cramer J; Masquelin T; Hipskind PA; Odingo J; Parish T
Bioorg Med Chem; 2017 Aug; 25(15):3922-3946. PubMed ID: 28576632
[TBL] [Abstract][Full Text] [Related]
4. Identification of 2-Amino Benzothiazoles with Bactericidal Activity against Mycobacterium tuberculosis.
Bonnett S; Jee JA; Chettiar S; Ovechkina Y; Korkegian A; Greve E; Odingo J; Parish T
Microbiol Spectr; 2023 Feb; 11(1):e0497422. PubMed ID: 36688635
[TBL] [Abstract][Full Text] [Related]
5. New small-molecule synthetic antimycobacterials.
Ballell L; Field RA; Duncan K; Young RJ
Antimicrob Agents Chemother; 2005 Jun; 49(6):2153-63. PubMed ID: 15917508
[No Abstract] [Full Text] [Related]
6. Structure-activity relationship of new anti-tuberculosis agents derived from oxazoline and oxazole benzyl esters.
Moraski GC; Chang M; Villegas-Estrada A; Franzblau SG; Möllmann U; Miller MJ
Eur J Med Chem; 2010 May; 45(5):1703-16. PubMed ID: 20116900
[TBL] [Abstract][Full Text] [Related]
7. Identification of SQ609 as a lead compound from a library of dipiperidines.
Bogatcheva E; Hanrahan C; Nikonenko B; de los Santos G; Reddy V; Chen P; Barbosa F; Einck L; Nacy C; Protopopova M
Bioorg Med Chem Lett; 2011 Sep; 21(18):5353-7. PubMed ID: 21807506
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships of antitubercular salicylanilides consistent with disruption of the proton gradient via proton shuttling.
Lee IY; Gruber TD; Samuels A; Yun M; Nam B; Kang M; Crowley K; Winterroth B; Boshoff HI; Barry CE
Bioorg Med Chem; 2013 Jan; 21(1):114-26. PubMed ID: 23211970
[TBL] [Abstract][Full Text] [Related]
9. Antitubercular Triazines: Optimization and Intrabacterial Metabolism.
Wang X; Inoyama D; Russo R; Li SG; Jadhav R; Stratton TP; Mittal N; Bilotta JA; Singleton E; Kim T; Paget SD; Pottorf RS; Ahn YM; Davila-Pagan A; Kandasamy S; Grady C; Hussain S; Soteropoulos P; Zimmerman MD; Ho HP; Park S; Dartois V; Ekins S; Connell N; Kumar P; Freundlich JS
Cell Chem Biol; 2020 Feb; 27(2):172-185.e11. PubMed ID: 31711854
[TBL] [Abstract][Full Text] [Related]
10. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.
Singh R; Manjunatha U; Boshoff HI; Ha YH; Niyomrattanakit P; Ledwidge R; Dowd CS; Lee IY; Kim P; Zhang L; Kang S; Keller TH; Jiricek J; Barry CE
Science; 2008 Nov; 322(5906):1392-5. PubMed ID: 19039139
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.
Gumbo T; Alffenaar JC
Clin Infect Dis; 2018 Nov; 67(suppl_3):S267-S273. PubMed ID: 30496455
[TBL] [Abstract][Full Text] [Related]
12. Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles.
Gurumurthy M; Mukherjee T; Dowd CS; Singh R; Niyomrattanakit P; Tay JA; Nayyar A; Lee YS; Cherian J; Boshoff HI; Dick T; Barry CE; Manjunatha UH
FEBS J; 2012 Jan; 279(1):113-25. PubMed ID: 22023140
[TBL] [Abstract][Full Text] [Related]
13. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis.
Manjunatha UH; Boshoff H; Dowd CS; Zhang L; Albert TJ; Norton JE; Daniels L; Dick T; Pang SS; Barry CE
Proc Natl Acad Sci U S A; 2006 Jan; 103(2):431-6. PubMed ID: 16387854
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of critical parameters in the hollow-fibre system for tuberculosis: A case study of moxifloxacin.
Aguilar-Ayala DA; Sanz-García F; Rabodoarivelo MS; Susanto BO; Bailo R; Eveque-Mourroux MR; Willand N; Simonsson USH; Ramón-García S; Lucía A;
Br J Clin Pharmacol; 2024 Jul; 90(7):1711-1727. PubMed ID: 38632083
[TBL] [Abstract][Full Text] [Related]
15. Whole cell hydride Meisenheimer complex biotransformation guided optimization of antimycobacterial benzothiazinones.
Joch M; Wojtas KP; Torres-Gómez H; Li Y; Meyer F; Straßburger M; Kerndl V; Dahse HM; Hertweck C; Hoffmann H; Görls H; Walter K; Hölscher C; Kloss F
Eur J Med Chem; 2024 Jan; 264():116023. PubMed ID: 38071794
[TBL] [Abstract][Full Text] [Related]
16. [Antitubercular substances of animal origin].
BARBOLINI G; VELLUTI G
Clin Ter; 1962 Mar; 22():525-55. PubMed ID: 13864893
[No Abstract] [Full Text] [Related]
17.
Dijkstra JA; van der Laan T; Akkerman OW; Bolhuis MS; de Lange WCM; Kosterink JGW; van der Werf TS; Alffenaar JWC; van Soolingen D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311078
[TBL] [Abstract][Full Text] [Related]
18. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.
Dookie N; Rambaran S; Padayatchi N; Mahomed S; Naidoo K
J Antimicrob Chemother; 2018 May; 73(5):1138-1151. PubMed ID: 29360989
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis.
Coll F; Phelan J; Hill-Cawthorne GA; Nair MB; Mallard K; Ali S; Abdallah AM; Alghamdi S; Alsomali M; Ahmed AO; Portelli S; Oppong Y; Alves A; Bessa TB; Campino S; Caws M; Chatterjee A; Crampin AC; Dheda K; Furnham N; Glynn JR; Grandjean L; Minh Ha D; Hasan R; Hasan Z; Hibberd ML; Joloba M; Jones-López EC; Matsumoto T; Miranda A; Moore DJ; Mocillo N; Panaiotov S; Parkhill J; Penha C; Perdigão J; Portugal I; Rchiad Z; Robledo J; Sheen P; Shesha NT; Sirgel FA; Sola C; Oliveira Sousa E; Streicher EM; Helden PV; Viveiros M; Warren RM; McNerney R; Pain A; Clark TG
Nat Genet; 2018 Feb; 50(2):307-316. PubMed ID: 29358649
[TBL] [Abstract][Full Text] [Related]
20. Repurposing and Revival of the Drugs: A New Approach to Combat the Drug Resistant Tuberculosis.
Sharma D; Dhuriya YK; Deo N; Bisht D
Front Microbiol; 2017; 8():2452. PubMed ID: 29321768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
